Cours suspendu

Communiqués VERE THER

Actions

VERV

US92539P1012

Marché Fermé - NYSE Autres places de cotation 22:00:00 24/07/2025			Varia. 5j.	Varia. 1 janv.
11,13 ^USD	+0,27%		-.--%	-

25/07/25	Verve Therapeutics, Inc. annonce des changements au sein de son conseil d'administration	CI
25/07/25	Ridgeway Acquisition Corporation finalise l'acquisition de 55,7 % de Verve Therapeutics pour 1,3 milliard de dollars	CI

Communiqués

25/07/25	Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk	PR
24/07/25	Lilly and Verve announce expiration of Verve tender offer	PR
19/06/25	VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV	BU
17/06/25	Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk	PR
02/06/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
28/05/25	Verve Therapeutics to Participate in Upcoming Investor Conferences	GL
14/05/25	Verve Therapeutics: Q1 Earnings Snapshot	AQ
14/05/25	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results	GL
14/05/25	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results	AQ
02/05/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
02/05/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	AQ
14/04/25	Verve Therapeutics : Initial Data from the Heart 2 Clinical Trial of VERVE 102.	PU
14/04/25	Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9	AQ
14/04/25	Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9	GL
11/04/25	Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9	AQ
11/04/25	Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9	GL
04/04/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
04/04/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	AQ
24/03/25	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose	GL
03/03/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
27/02/25	Verve Therapeutics: Q4 Earnings Snapshot	AQ
27/02/25	Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results	GL
03/02/25	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
31/01/25	Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm	PR
29/01/25	Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference	GL